Clinical Trials on Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Re

Total 6549 results

Cantargia AB

Active, not recruiting

A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR)

Colorectal Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma

Austria, Denmark, Germany, Belgium, Spain, Latvia, Netherlands, Lithuania, Estonia, Sweden, Norway
The Methodist Hospital Research Institute
Merck Sharp & Dohme LLC

Completed

SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (STOMP)

Metastatic Non-small Cell Lung Cancer | Metastatic Triple-negative Breast Cancer

United States
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

United States, Spain, Taiwan, Germany, Netherlands, United Kingdom, Korea, Republic of
Memorial Sloan Kettering Cancer Center

Recruiting

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Non Small Cell Lung Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Metastatic Non-Small Cell Lung Carcinoma

United States
AbbVie

Active, not recruiting

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Cancer | Advanced Solid Tumors | Metastatic Solid Tumors | Triple-Negative Breast Cancer (TNBC) | Non-small-cell-lung-cancer (NSCLC)

United States, Australia, France, Israel, Spain, Taiwan
Pfizer

Terminated

Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

Non-Small Cell Lung Cancer | Triple-negative Breast Cancer

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | TNBC - Triple-Negative Breast Cancer | NSCLC Stage IV Without EGFR/ALK Mutation

United States, Canada
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL797 in Adults With Solid Tumors

Advanced Breast Cancer | NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Recurrent Breast Cancer | TNBC - Triple-Negative Breast Cancer | Relapsed Cancer | NSCLC, Recurrent | Recurrent... and other conditions

United States
Daiichi Sankyo Co., Ltd.
AstraZeneca; Daiichi Sankyo, Inc.

Recruiting

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast Cancer

United States, Japan
National Cancer Institute (NCI)
AstraZeneca

Active, not recruiting

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Advanced Malignant Solid Neoplasm | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IIIA Lung Non-Small... and other conditions

United States, Canada
Queen Mary University of London
AstraZeneca; Cancer Research UK

Unknown

A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers (TORCMEK)

Squamous Cell Lung Cancer | Triple-Negative Breast Cancer | Non-squamous Cell Lung Cancer With KRAS Mutations | Non-squamous Cell Lung Cancer With Wild-type KRAS

United Kingdom
Merrimack Pharmaceuticals

Completed

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Colorectal Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Triple Negative Breast Cancer | Squamous Cell Head and Neck Cancer

United States
AstraZeneca

Completed

AZD8186 First Time In Patient Ascending Dose Study

Advanced Castrate-resistant Prostate Cancer CRPC | Squamous Non-Small Cell Lung Cancer sqNSCLC | Triple Negative Breast Cancer TNBC

Spain, Canada, United States, United Kingdom
Merrimack Pharmaceuticals
Sanofi

Completed

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Colorectal Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Squamous Cell Head and Neck Cancer | Other Tumors With EGFR Dependence

United States
Silverback Therapeutics

Withdrawn

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Urothelial Carcinoma | Hormone Receptor-positive/HER2-negative Breast Cancer
Western Regional Medical Center

Withdrawn

Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)

Metastatic Non-Small Cell Lung Cancer | Metastatic Colon Cancer | Metastatic Triple Negative Breast Cancer

United States
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Solid Tumors | ER+ Breast Cancer | ARID1A Gene Mutation | Triple Negative Breast Cancer, TNBC | Small Cell Lung Cancer, SCLC

United States, China
Cofactor Genomics, Inc.
Curebase Inc.

Recruiting

A Multicenter Cancer Biospecimen Collection Study

Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Triple Negative Breast Cancer | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Cancer of Head and Neck | Lung Cancer, Nonsmall Cell | Gastroesophageal Junction Adenocarcinoma

United States
GB006, Inc., a wholly owned subsidiary of Gossamer...
Merck Sharp & Dohme LLC

Terminated

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Renal Cell Carcinoma | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Castration-resistant Prostate Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Adenocarcinoma | Esophageal... and other conditions

United States, United Kingdom
VastBiome

Recruiting

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors (PARADIGM)

Renal Cell Carcinoma | Non-Small-Cell Lung Carcinoma | Malignant Melanoma | Triple-Negative Breast Cancer

United States
Merck Sharp & Dohme LLC

Terminated

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Non-small Cell Lung Cancer (NSCLC) | Triple Negative Breast Cancer (TNBC) | NUT Midline Carcinoma (NMC) | Castration-resistant Prostate Cancer (CRPC)
A&G Pharmaceutical Inc.
University of Maryland Greenebaum Cancer Center

Recruiting

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

Non Small Cell Lung Cancer | Mesothelioma | Triple Negative Breast Cancer | Hormone-Resistant Breast Cancer

United States
NeoImmuneTech
Merck Sharp & Dohme LLC

Active, not recruiting

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60)

Small Cell Lung Cancer | Pancreatic Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Microsatellite Stable Colorectal Cancer | Any Advanced Solid Tumors

United States
Case Comprehensive Cancer Center

Withdrawn

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

Small Cell Lung Cancer | Non Small Cell Lung Cancer | Mesothelioma | Urothelial Cancer | Malignant Melanoma | Advanced Triple Negative Breast Cancer
Novartis Pharmaceuticals

Terminated

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Ovarian Cancer | Non-small Cell Lung Cancer (NSCLC) | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Colorectal Cancer Microsatellite Stable (MSS)

Canada, Australia, Singapore, United States, Japan, Spain, United Kingdom
AstraZeneca
Daiichi Sankyo

Active, not recruiting

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

Carcinoma, Non-Small-Cell Lung | Triple Negative Breast Cancer

China
Sellas Life Sciences Group
Merck Sharp & Dohme LLC; Cancer Insight, LLC

Active, not recruiting

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Colorectal Cancer | Ovarian Cancer | Acute Myelogenous Leukemia | Small-cell Lung Cancer | Triple-negative Breast Cancer

United States
MacroGenics

Completed

Safety Study of MGA271 in Refractory Cancer

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Triple-negative Breast Cancer

United States
Lyell Immunopharma, Inc.
ICON plc

Recruiting

A Biomarker Screening Protocol for Participants With Solid Tumors (START)

Triple Negative Breast Cancer | Nonsmall Cell Lung Cancer

United States
Evelo Biosciences, Inc.
Merck Sharp & Dohme LLC; SCRI Development Innovations, LLC

Completed

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Renal Cell Carcinoma | Non Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | Colorectal Cancer Metastatic | GastroEsophageal Cancer | MSI-H

United States, Canada
Southwest Oncology Group
Patient-Centered Outcomes Research Institute; National Cancer Institute (NCI)

Completed

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) (TrACER)

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Febrile Neutropenia | Stage 0 Breast Cancer | Stage IV Non-Small Cell Lung Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast... and other conditions

United States, Puerto Rico
CytosinLab Therapeutics Co., Ltd.

Recruiting

CTS2190 Phase I /II Clinical Study in Patients

Pancreatic Cancer | Non-small Cell Lung Cancer | Solid Tumors | Triple-negative Breast Cancer

China
Oncoethix GmbH

Completed

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castrate-resistant Prostate Cancer | CRPC | NUT Midline Carcinoma | Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

United States, France, Taiwan, Canada, Italy, Singapore, Belgium, Spain, Israel
Chimerix

Withdrawn

A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer

Advanced Colorectal Cancer | Advanced Glioblastoma | Advanced Triple-negative Breast Cancer | Advanced Non-small Cell Lung Cancer

United States
Bolt Biotherapeutics, Inc.

Recruiting

Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies

Clear Cell Renal Cell Carcinoma | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer

United States
Valo Therapeutics Oy

Recruiting

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Colorectal Cancer | Non-Small Cell Lung Cancer | Melanoma (Skin) | Myxoid Liposarcoma | Synovial Sarcoma | Triple-Negative Breast Cancer

Germany
Andrei Iagaru
National Cancer Institute (NCI)

Completed

18F-FSPG PET/CT for Cancer Patients on Therapy

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Metastatic Renal Cell Cancer | Stage III Renal Cell Cancer | Stage IV Non-Small Cell Lung Cancer | Stage IV Breast Cancer | B-Cell Neoplasm | Stage IIIA Breast Cancer | Stage IV Renal Cell Cancer | Stage IIIC Breast Cancer | Estrogen... and other conditions

United States
Gustave Roussy, Cancer Campus, Grand Paris

Withdrawn

Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors (MATILDA)

Metastatic Colorectal Cancer | Triple Negative Breast Cancer | Esophageal Adenocarcinoma | Prostate Adenocarcinoma | Stomach Adenocarcinoma
Memgen, Inc.
H. Lee Moffitt Cancer Center and Research Institute; Duke Cancer Institute

Recruiting

MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Solid Tumor | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Advanced Cancer | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (PIVOT-02)

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Urothelial Carcinoma | HR+/HER2- Breast Cancer

United States, Spain, Canada, France, Italy, Belgium, Poland, United Kingdom
Celldex Therapeutics
Genentech, Inc.

Terminated

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Melanoma | Neoplasms | Neoplasms by Histologic Type | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Head and Neck Cancer | Bladder Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Clear-cell Metastatic Renal Cell Carcinoma

United States
Hummingbird Bioscience
Merck Sharp & Dohme LLC

Recruiting

A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab

Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Nonsmall Cell Lung Cancer | Malignant Neoplasm | Tumor, Solid

United States
Eli Lilly and Company

Terminated

A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Triple Negative Breast Cancer

Belgium, Spain, United States, France, Italy, Denmark
Fred Hutchinson Cancer Center
SignalOne Bio, Inc.

Terminated

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Metastatic Triple-Negative Breast Carcinoma

United States
Tempest Therapeutics

Completed

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Urothelial Carcinoma | GastroEsophageal Cancer | Triple-Negative Breast Cancer | Metastatic Castration Resistant Prostate...

United States
Incyte Corporation

Completed

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castration Resistant Prostate Cancer | Gastric/ Gastroesophageal Junction | Squamous Carcinoma...

United States, Spain, France, United Kingdom, Italy, Belgium
Genmab

Terminated

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

Renal Cell Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Urothelial Cancer

United States, United Kingdom, Spain
Salubris Biotherapeutics Inc

Recruiting

A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients With Unresectable Locally Advanced or Metastatic Cancer

Melanoma | Clear Cell Renal Cell Carcinoma | Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Advanced Solid Tumor | Epithelial Ovarian Cancer | Non-small Cell... and other conditions

Belgium, Spain
Mabpro, a.s.

Not yet recruiting

Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours (CAMP1)

Head and Neck Cancer | Mesothelioma, Malignant | TNBC - Triple-Negative Breast Cancer | Non-small-cell Lung Carcinoma | Clear Cell Renal Cell Carcinoma Metastatic

Clinical Trials on Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Re

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations